XLON
THAT
Market cap6mUSD
Oct 30, Last price
0.58GBP
1D
0.00%
1Q
-14.81%
IPO
-99.18%
Name
N4 Pharma PLC
Chart & performance
P/E
—
P/S
657.18
EPS
—
Vol. 1Y
57.85%
Shs. 5Y
27.75%
Rev. 5Y
-60.78%
Div Yld LY
—
Div Yld TTM
—
Revenues
7k
+272.86%
Net income
-1m
L-16.55%
CFO
-972k
L-19.65%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular uptake and effectiveness of various cancer treatments and vaccines. The company's product portfolio includes Nuvec, a unique silica nanoparticle delivery platform distinguished by its irregular surface structure that effectively encapsulates and safeguards genetic material such as siRNA, RNA, and DNA. Additionally, it offers Liptide, a specialized platform engineered for the targeted delivery of a proprietary siRNA sequence to silence fibrotic genes. Thalia Therapeutics is also advancing N4 101, an orally administered inflammation inhibitor currently undergoing pre-clinical evaluation for the treatment of inflammatory bowel disease, alongside ECP105, which is being developed to prevent ocular scarring. The firm, previously known as N4 Pharma Plc, officially rebranded to Thalia Therapeutics Plc in March 2026.
Key people
Executive Director · since 2020
Nigel Theobald
Chief Executive Officer, Executive Director
Simon Bennett
Director - Commercial
Fiona Mclaughlin
Head - Research and Development
Non-Executive Director · since 2025
Christopher Britten
Non-Executive Independent Chairman of the Board · since 2023
Michael Palfreyman
Non-Executive Independent Director · since 2024
Alastair Smith
Non-Executive Independent Director · since 2025
Headquarters & legal address
C/O ARCH LAW HUCKLETREE BISHOPSGATE
8 BISHOPSGATE
LONDON, LND EC2N 4BQ
GB
8 BISHOPSGATE
LONDON, LND EC2N 4BQ
GB
Previous name
ONZIMA VENTURES PLC
Previous name
ULTIMA NETWORKS PLC
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||